Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease

Neurology

Volumn 91, Issue 14, 2018, Pages E1295-E1306

  McDade, Eric ^a   Wang, Guoqiao ^a   Gordon, Brian A ^a   Hassenstab, Jason ^a   Benzinger, Tammie L S ^a   Buckles, Virginia ^a   Fagan, Anne M ^a   Holtzman, David M ^a   Cairns, Nigel J ^a   Goate, Alison M ^b   Marcus, Daniel S ^c   Morris, John C ^a   Paumier, Katrina ^a   Xiong, Chengjie ^a   Allegri, Ricardo ^d   Berman, Sarah B ^e   Klunk, William ^e   Noble, James ^f   Ringman, John ^g   Ghetti, Bernardino ^h   Farlow, Martin ^h   Sperling, Reisa A ⁱ   Chhatwal, Jasmeer ⁱ   Salloway, Stephen ^j   Graff Radford, Neill R ^k   Schofield, Peter R ^l,m   Masters, Colin ⁿ   Rossor, Martin N ^o   Fox, Nick C ^p   Levin, Johannes ^g,p   Jucker, Mathias ^o,q   Bateman, Randall J ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e Columbia University ^*  (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g INDIANA UNIVERSITY   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ BROWN UNIVERSITY   (United States)

^j MAYO CLINIC   (United States)

^k NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^l UNIVERSITY OF NEW SOUTH WALES   (Australia)

^m UNIVERSITY OF MELBOURNE   (Australia)

ⁿ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^o GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^p UNIVERSITY OF MUNICH   (Germany)

^q UNIVERSITY OF TÜBINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN; AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; BIOLOGICAL MARKER; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRESENILIN 1; PRESENILIN 2; PSEN1 PROTEIN, HUMAN; PSEN2 PROTEIN, HUMAN;

ADULT; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; BRAIN ATROPHY; BRAIN FUNCTION; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSESSMENT; DISEASE COURSE; FEMALE; GENE MUTATION; HETEROZYGOTE; HIPPOCAMPUS; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; BRAIN; COGNITION; DIAGNOSTIC IMAGING; DOMINANT GENE; FOLLOW UP; GENETICS; MUTATION; PHOSPHORYLATION; PSYCHOLOGY; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL DOMINANT INHERITANCE; BRAIN METABOLISM; CLINICAL ASSESSMENT; COGNITIVE DEFECT; DISEASE MARKER; MAJOR CLINICAL STUDY; METABOLIC DISORDER; NEUROIMAGING; PROTEIN CEREBROSPINAL FLUID LEVEL; SYMPTOM; TAU PROTEIN CEREBROSPINAL FLUID LEVEL;

ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; BIOMARKERS; BRAIN; COGNITION; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENES, DOMINANT; HETEROZYGOTE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PRESENILIN-1; PRESENILIN-2; TAU PROTEINS;

EID: 85054053786     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000006277     Document Type: Article

References (33)

1. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795-804.
2. Mills SM, Mallmann J, Santacruz AM, et al. Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial. Rev Neurol 2013;169:737-743.
3. Fleisher AS, Chen K, Quiroz YT, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: A crosssectional study. JAMA Neurol 2015;72:316-324.
4. Fox NC, Warrington EK, Seiffer AL, Agnew SK, Rossor MN. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease: A longitudinal prospective study. Brain 1998;121:1631-1639.
5. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study. Lancet Neurol 2012;11:1048-1056.
6. Wallon D, Rousseau S, Rovelet-Lecrux A, et al. The French series of autosomal dominant early onset Alzheimer's disease cases: Mutation spectrumand cerebrospinal fluid biomarkers. J Alzheimers Dis 2012;30:847-856.
7. Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008;71:85-92.
8. Cash DM, Ridgway GR, Liang Y, et al. The pattern of atrophy in familial Alzheimer disease: Volumetric MRI results from the DIAN study. Neurology 2013;81:1425-1433.
9. Chhatwal JP, Schultz AP, Johnson K, et al. Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology 2013;81:736-744.
10. Ringman JM, Liang LJ, Zhou Y, et al. Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. Brain 2015;138:1036-1045.
11. Storandt M, Balota DA, Aschenbrenner AJ, Morris JC. Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). Neuropsychology 2014;28:19-29.
12. Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron 2013;80:1347-1358.
13. Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis. Neurology 2014;83:253-260.
14. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: Stopping AD before symptoms begin? Sci Transl Med 2014;6:228fs13.
15. Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011; 26(suppl 3):321-329.
16. Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Invest 2012;2:975-984.
17. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993;43:2412-2414.
18. Bateman RJ, Benzinger TL, Berry S, et al. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement 2017;13:8-19.
19. Benzinger TL, Blazey T, Jack CR Jr, et al. Regional variability of imaging biomarkers in autosomal dominantAlzheimer's disease. ProcNatl Acad Sci USA 2013;110:E4502-E4509.
20. Su Y, D'Angelo GM, Vlassenko AG, et al. Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One 2013;8:e73377.
21. Su Y, Blazey TM, Owen CJ, et al. Quantitative amyloid imaging in autosomal dominant Alzheimer's disease: Results from the DIAN study group. PLoS One 2016;11:e0152082.
22. Cleveland WS, Devlin SJ, Grosse E. Regression by local fitting: Methods, properties, and computational algorithms. J Econom 1988;37:87-114.
23. Jack CR, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013;81:1732-1740.
24. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 2013;12:357-367.
25. Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain 2016; 139:1226-1236.
26. Palmqvist S, Schöll M, Strandberg O, et al. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun 2017;8:1214.
27. Fagan AM, Xiong C, Jasielec MS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med 2014;6:226ra30.
28. Yamada K, Cirrito JR, Stewart FR, et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci 2011;31:13110-13117.
29. Potter R, Patterson BW, Elbert DL, et al. Increased in vivo Amyloid-Beta 42 production, exchange, and irreversible loss in presenilin mutations carriers. Sci Transl Med 2013;5:189ra77.
30. Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI. Acta Neuropathol 2013;126:659-670.
31. Sutphen CLML, Herries EM, Xiong C, Ladenson JH, Holtzman DM, Fagan AM. Longitudinal decrease in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer disease. Alzheimers Dement 2018;14:869-879.
32. Jack CR, Wiste HJ, Knopman DS, et al. Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology 2014;82:1605-1612.
33. Gordon BA, Blazey TM, Su Y, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: A longitudinal study. Lancet Neurol 2018;17:241-250.